证券代码：603658 证券简称：安图生物 公告编号：2025-038 郑州安图生物工程股份有限公司 关于使用闲置募集资金进行现金管理 赎回及进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1 现金管理种类：大额存单 现金管理金额：33,000 万元非公开发行股票闲置募集资金； 履行的审议程序：郑州安图生物工程股份有限公司（以下简称"公司"）于 2024 年 12 月 11 日召开第五届董事会第二次会议、第五届监事会第二次会 议，审议通过《关于使用部分闲置募集资金进行现金管理的议案》，同意 公司在确保不影响募集资金投资项目建设和募集资金使用的情况下，公司 拟分别使用不超过 1.7 亿元公开发行可转换公司债券闲置募集资金和不超 过 17 亿元非公开发行股票闲置募集资金进行现金管理，分别用于购买单次 持有期限不超过 12 个月的结构性存款、大额存单、国债逆回购、券商收益 凭证、券商理财产品等安全性高、流动性好的保本型产品。在上述额度范 围内，资金可在 12 个月内滚动使用。具体内容详见公司于 2024 ...

证券代码：603658 证券简称：安图生物 公告编号：2025-037 （二）现金管理金额 公司非公开发行股票闲置募集资金 25,000 万元 郑州安图生物工程股份有限公司 关于使用闲置募集资金进行现金管理 赎回及进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1 现金管理种类：大额存单 现金管理金额：25,000 万元非公开发行股票闲置募集资金； 履行的审议程序：郑州安图生物工程股份有限公司（以下简称"公司"）于 2024 年 12 月 11 日召开第五届董事会第二次会议、第五届监事会第二次会 议，审议通过《关于使用部分闲置募集资金进行现金管理的议案》，同意 公司在确保不影响募集资金投资项目建设和募集资金使用的情况下，公司 拟分别使用不超过 1.7 亿元公开发行可转换公司债券闲置募集资金和不超 过 17 亿元非公开发行股票闲置募集资金进行现金管理，分别用于购买单次 持有期限不超过 12 个月的结构性存款、大额存单、国债逆回购、券商收益 凭证、券商理财产品等安全性高、流动性好的保本型产品。在上述额度 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603658 证券简称：安图生物 公告编号：2025-036 郑州安图生物工程股份有限公司 关于开立募集资金现金管理产品专用结算账户的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 郑州安图生物工程股份有限公司（以下简称"公司"）于2024年12月11日召开第五届董事会第二次会议、 第五届监事会第二次会议，审议通过《关于使用闲置募集资金进行现金管理的议案》，同意公司在确保 不影响募集资金投资项目建设和募集资金使用的情况下，公司拟分别使用不超过1.7亿元公开发行可转 换公司债券闲置募集资金和不超过17亿元非公开发行股票闲置募集资金进行现金管理，分别用于购买单 次持有期限不超过12个月的结构性存款、大额存单、国债逆回购、券商收益凭证、券商理财产品等安全 性高、流动性好的保本型产品。在上述额度范围内，资金可在12个月内滚动使用。具体内容详见公司于 2024年12月12日在上海证券交易所网站（www.sse.com.cn）披露的《安图生物关于使用闲置募集资金进 行现金 ...

Investment Rating - The investment rating for the company is "Buy" indicating an expected relative price increase of over 20% compared to the market benchmark index within the next six months [22]. Core Views - The company's performance is under short-term pressure, with expectations for recovery driven by overseas expansion and domestic market recovery [2][4]. - The company reported a revenue of 4.471 billion (up 0.62% year-on-year) and a net profit of 1.194 billion (down 1.89% year-on-year) for 2024, while Q1 2025 saw a revenue of 996 million (down 8.56% year-on-year) and a net profit of 270 million (down 16.76% year-on-year) [3][5]. - The company is actively responding to centralized procurement impacts, with expectations for recovery in the second quarter of 2026 [5]. Financial Performance - In 2024, the company achieved revenue of 25.56 billion in immunodiagnostics (up 2.91% year-on-year), while biochemical testing revenue was 2.22 billion (down 11.21% year-on-year), and microbiological testing revenue was 3.61 billion (up 11.48% year-on-year) [5]. - The overseas business generated revenue of 284 million in 2024 (up 36.25% year-on-year), indicating strong growth potential [6]. - The company maintained stable expense ratios, with a sales expense ratio of 17.2%, management expense ratio of 4.7%, and R&D expense ratio of 16.4% (up 1.6 percentage points) [6]. Product Development and Market Position - The company launched new products including the AutoChem B2000 and B8000 series of fully automated biochemical analyzers, and the Autof T series of microbial mass spectrometry detection systems [6]. - In the NGS segment, the company’s subsidiary successfully launched three gene sequencers and an automated pathogen analysis system, with further products in trial production [6]. Earnings Forecast and Valuation - The earnings per share (EPS) forecast for 2025-2027 is 2.2, 2.6, and 3.0 respectively, with corresponding price-to-earnings (PE) ratios of 17, 15, and 13 [7]. - The company is recognized as a pioneer in the domestic IVD platform, with increased R&D investment expected to enhance competitiveness [7].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 郑州安图生物工程股份有限公司（以下简称"公司"）于2024年12月11日召 开第五届董事会第二次会议、第五届监事会第二次会议，审议通过《关于使用闲 置募集资金进行现金管理的议案》，同意公司在确保不影响募集资金投资项目建 设和募集资金使用的情况下，公司拟分别使用不超过1.7亿元公开发行可转换公 司债券闲置募集资金和不超过17亿元非公开发行股票闲置募集资金进行现金管 理，分别用于购买单次持有期限不超过12个月的结构性存款、大额存单、国债逆 回购、券商收益凭证、券商理财产品等安全性高、流动性好的保本型产品。在上 述额度范围内，资金可在12个月内滚动使用。具体内容详见公司于2024年12月12 日在上海证券交易所网站（www.sse.com.cn）披露的《安图生物关于使用闲置募 集资金进行现金管理的公告》（公告编号：2024-093）。 证券代码：603658 证券简称：安图生物 公告编号：2025-036 郑州安图生物工程股份有限公司 关于开立募集资金现金管理产品专用结算账户的 公告 ...

Investment Rating - The investment rating for the company is "Buy" [6][12] Core Views - The company is a leading player in the in vitro diagnostics sector, with a diversified business layout that continues to grow [6][12] - In 2024, the company is expected to achieve revenue of 4.471 billion yuan, representing a growth of 0.62%, while the net profit attributable to the parent company is projected to be 1.194 billion yuan, a decrease of 1.89% [6][12] - The company's main business operations are stable, with notable performance in molecular diagnostics and overseas markets [2][6] Financial Performance Summary - For 2024, the company's revenue is projected to be 44.71 billion yuan, with a slight increase of 0.62%, and the net profit is expected to be 11.94 billion yuan, down by 1.89% [2][4] - In Q1 2025, the company reported revenue of 9.96 billion yuan, a decrease of 8.56%, and a net profit of 2.70 billion yuan, down by 16.76% [2][4] - The revenue from the reagent segment in 2024 is expected to be 37.97 billion yuan, with immunodiagnostic products contributing 25.56 billion yuan, an increase of 2.91% [2][4] - The company achieved domestic revenue of 41.05 billion yuan in 2024, a decrease of 1.30%, while overseas revenue reached 2.84 billion yuan, an increase of 36.25% [2][4] Research and Development Summary - The company increased its R&D investment to 7.32 billion yuan in 2024, a year-on-year increase of 11.55% [2][4] - In 2024, the company registered 144 new reagent product certificates, covering advanced technology fields such as chemiluminescence and molecular diagnostics [2][4] - The launch of the AutoChem B2000/B800 series of fully automated biochemical analyzers marks a significant development in the biochemical product field [2][4] Profitability and Financial Ratios - The company's gross margin for 2024 is projected to be 65.41%, reflecting a stable performance [2][4] - The sales, management, and R&D expense ratios for 2024 are expected to be 17.17%, 4.72%, and 16.37%, respectively [2][4] - The projected EPS for 2025, 2026, and 2027 are 2.24 yuan, 2.66 yuan, and 3.08 yuan, respectively [2][4]

Core Points - The company announced a cash dividend of 1.26 yuan per share for its A shares [1] - The total cash dividend distribution amounts to approximately 720 million yuan based on the total share capital of 571,424,768 shares [1] - The dividend distribution plan was approved at the annual shareholders' meeting held on May 8, 2025 [1] Dividend Distribution Details - The record date for the dividend is May 23, 2025, with the last trading date and ex-dividend date both set for May 26, 2025 [1] - The cash dividends will be distributed through China Securities Depository and Clearing Corporation Limited Shanghai Branch [1][2] - For individual shareholders and securities investment funds, the actual cash dividend after tax will be 1.26 yuan per share, with specific tax implications based on holding periods [3][4] Tax Implications - Individual shareholders holding shares for less than or equal to one month will incur a tax rate of 20% on the dividend [3] - Shareholders holding shares for more than one month but less than or equal to one year will have a reduced tax rate of 10% [3] - Shareholders holding shares for over one year will be exempt from personal income tax on the dividend [3] QFII and Other Investors - Qualified Foreign Institutional Investors (QFII) will have a 10% withholding tax applied, resulting in an actual cash dividend of 1.134 yuan per share [4][5] - Hong Kong market investors will also face a 10% withholding tax, leading to the same net dividend of 1.134 yuan per share [5] - Other institutional investors are responsible for their own tax payments, receiving the gross dividend of 1.26 yuan per share [5]

证券代码：603658 证券简称：安图生物 公告编号：2025-035 郑州安图生物工程股份有限公司2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利1.26元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/5/23 | － | 2025/5/26 | 2025/5/26 | 差异化分红送转： 否 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 8 日的2024年年度股东大会审议通过。 本次利润分配以方案实施前的公司总股本571,424,768股为基数，每股派发现金红利1.26 元（含税），共计派发现金红利719,995,207.68元。 1. 发放年度：2024年年度 2. 分派对象： 三、 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红 ...

特此公告。 证券代码：603658 证券简称：安图生物 公告编号：2025-034 郑州安图生物工程股份有限公司董事会 2025 年 5 月 14 日 郑州安图生物工程股份有限公司 关于参加河南辖区上市公司 2025 年投资者网上集体 接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为进一步加强与投资者的互动交流，郑州安图生物工程股份有限公司（以下 简称"公司"）定于 2025年5月22日（周四）15:25-16:55 参加在全景网举办的 河南辖区上市公司2025年投资者网上集体接待日活动，本次活动将采用网络远程 的方式举行，投资者可登录 "全景 • 路演天下"（http://rs.p5w.net）参与本次 互动交流。 出席本次网上集体接待日活动的人员为公司副总经理兼董事会秘书房瑞宽 先生（如有特殊情况，参会人员将可能进行调整），届时将通过网络在线问答互 动的形式，与投资者就其关注的问题进行交流。欢迎广大投资者积极参与。 ...

Core Viewpoint - The company reported its 2024 annual results and Q1 2025 results, showing a slight revenue increase but a decline in net profit, with significant growth in overseas revenue indicating improved international competitiveness [1][2]. Group 1: Financial Performance - In 2024, the company achieved revenue of 4.471 billion yuan, a year-over-year increase of 0.62%, while the net profit attributable to shareholders was 1.194 billion yuan, a decrease of 1.89% [1]. - For Q1 2025, the company reported revenue of 996 million yuan, a year-over-year decline of 8.56%, with a net profit of 270 million yuan, down 16.76% year-over-year [1]. - Domestic business revenue was 4.105 billion yuan, a decrease of 1.30%, primarily due to policy impacts, while overseas revenue reached 284 million yuan, reflecting a growth of 36.25% [1]. Group 2: Research and Development - The company maintained a strong focus on R&D, with R&D expenses amounting to 732 million yuan, representing 16.37% of total revenue, indicating a commitment to innovation [2]. - The gross profit margin for 2024 was 65.41%, an increase of 0.34 percentage points, while the net profit margin was 26.82%, a decrease of 0.73 percentage points due to rising R&D costs [2]. - The company plans to continue focusing on cutting-edge technologies in molecular diagnostics, immunodiagnostics, and POCT to drive innovation and product upgrades [2]. Group 3: Future Outlook - The company is expected to achieve revenues of 4.773 billion yuan, 5.811 billion yuan, and 6.972 billion yuan for 2025, 2026, and 2027, respectively, with year-over-year growth rates of 6.75%, 21.75%, and 19.97% [3]. - Projected net profits for the same years are 1.280 billion yuan, 1.560 billion yuan, and 1.876 billion yuan, with growth rates of 7.20%, 21.80%, and 20.28% [3]. - The company is rated as a strong player in the in vitro diagnostics sector, maintaining a "buy" rating [3].